1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D668A70B43B56C078525828A004F0B0F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/value-relationships-with-external-groups-advocacy-groups-and-guidelines-organizations?opendocument
18
19opendocument
2054.198.246.164
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

How Medical Affairs Creates Value & Relationships with External Groups: Advocacy Groups and Guidelines Organizations

ID: 5508


Features:

10 Info Graphics

17 Data Graphics

300 Metrics


Pages/Slides: 35


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "How Medical Affairs Creates Value & Relationships with External Groups: Advocacy Groups and Guidelines Organizations"

STUDY OVERVIEW

Medical Affairs groups face a constantly evolving healthcare landscape that requires Medical Affairs leadership to continually adjust what external groups they work with and how they work with them. Advocacy groups and guidelines organizations are among the external groups that Medical Affairs interact with to provide medical support for their organization.

But its not always clear which Medical Affairs functions and activities resonate best with these two dissimilar external groups. To provide current insights into how pharma companies are serving advocacy groups and guidelines organizations, Best Practices, LLC performed this research study to probe Medical Affairs' roles, tools, effectiveness and success metrics in serving these external stakeholders.

This study will help Medical Affairs leaders identify the tools, activities, services that peers are utilizing to interact with advocacy groups and guidelines organizations. It also provides key performance indicators and best practices to demonstrate value to these groups.

KEY TOPICS

  • Executive Summary
  • Interactions with External Groups
  • Tools, Roles, Services, KPIs and Interactions Timeline: Advocacy Groups
  • Tools, Roles, Services, KPIs and Interactions Timeline: Guidelines Organizations
  • Benchmark Participant Demographics

SAMPLE KEY METRICS

  • What external groups does your Medical Affairs organization work with
  • How important are these external groups to your Medical Affairs organization
  • How effective is your Medical Affairs organization's work with these external groups
  • Which functions within your Medical Affairs organization have a role with advocacy groups
  • What tools does your Medical Affairs organization use to showcase value to advocacy groups
  • Rate the effectiveness of these tools used with advocacy groups
  • What are your key performance indicators for working with advocacy groups
  • What activities does your Medical Affairs organization conduct with advocacy groups
  • Which functions within your Medical Affairs organization have a role with guidelines organizations
  • What tools does your Medical Affairs organization use to showcase value to guidelines organizations
  • Rate the effectiveness of these tools used with guidelines organizations
  • What are your key performance indicators for working with guidelines organizations
  • What activities does your Medical Affairs organization conduct with guidelines organizations

SAMPLE KEY FINDINGS

  • Timeline of Advocacy Group Interactions: The importance of Advocacy Groups picks up during the launch phase with 86% of respondents rating Advocacy Groups very important. During the pre-launch and brand building, 48% and 63% respectively rate Advocacy Groups very important. Once the product reaches maturity, Advocacy Groups remain very important only for 28%.
  • Timeline of Guidelines Organizations Interactions: The importance of Guideline Organizations picks up during the launch phase and remains important during the brand building with 84% and 79% of respondents rating Guideline Organizations very important. Once the product reaches maturity, Guideline Organizations slip to being very important to less than one-quarter of companies.

METHODOLOGY

For this research, Best Practices, LLC engaged 50 Medical Affairs experts at 33 companies through a benchmarking survey. Research participants include Chief Medical Officer (CMO), VPs, Heads, Directors, Managers/Leaders and Specialists.


Industries Profiled:
Biotech; Chemical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Communications


Companies Profiled:
Genentech; Boehringer Ingelheim; Novartis; EMD Serono; Bayer; Roche; Amgen; Novo Nordisk; Astellas; Shire; Abbott; Pfizer; Sanofi; Sandoz; Takeda Pharmaceuticals; Santen; Vifor Pharma; cipla; Siemens Healthcare; UCB Pharma; Roche Diagnostics; Teva Pharmaceutical Industries Ltd; Sanofi Genzyme; Jazz Pharmaceuticals; Janssen; Ferring Pharmaceuticals; Upsher-Smith; Seattle Genetics; Otonomy; CSL Behring; Sunovion; Tillotts Pharma; ApotheCom

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.